Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $33.5 in the last session, up 2.01% from day before closing price of $32.84. In other words, the price has increased by $2.01 from its previous closing price. On the day, 2.49 million shares were traded. RARE stock price reached its highest trading level at $34.005 during the session, while it also had its lowest trading level at $32.65.
Ratios:
We take a closer look at RARE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 94.23 whereas as Long-Term Debt/Eq ratio is at 85.75.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $65.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 10 ’25 when Horn Howard sold 3,081 shares for $36.38 per share. The transaction valued at 112,087 led to the insider holds 95,146 shares of the business.
HOWARD HORN bought 3,081 shares of RARE for $112,087 on Dec 10 ’25. On Oct 13 ’25, another insider, Horn Howard, who serves as the Chief Financial Officer of the company, sold 7,942 shares for $31.51 each. As a result, the insider received 250,252 and left with 98,227 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3231998464 and an Enterprise Value of 3671066880. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.13 while its Price-to-Book (P/B) ratio in mrq is 352.11. Its current Enterprise Value per Revenue stands at 5.822 whereas that against EBITDA is -7.217.
Stock Price History:
The Beta on a monthly basis for RARE is 0.13, which has changed by -0.23638022 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $46.50, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -0.71%, while the 200-Day Moving Average is calculated to be -0.22%.
Shares Statistics:
According to the various share statistics, RARE traded on average about 1.49M shares per day over the past 3-months and 1763020 shares per day over the past 10 days. A total of 96.27M shares are outstanding, with a floating share count of 89.77M. Insiders hold about 6.95% of the company’s shares, while institutions hold 99.09% stake in the company. Shares short for RARE as of 1764288000 were 8871538 with a Short Ratio of 5.94, compared to 1761868800 on 7144800. Therefore, it implies a Short% of Shares Outstanding of 8871538 and a Short% of Float of 9.520000000000001.
Earnings Estimates
As of right now, 12.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.47, with high estimates of -$0.91 and low estimates of -$1.77.
Analysts are recommending an EPS of between -$5.33 and -$6.41 for the fiscal current year, implying an average EPS of -$5.77. EPS for the following year is -$4.47, with 12.0 analysts recommending between -$2.68 and -$6.41.
Revenue Estimates
According to 16 analysts,. The current quarter’s revenue is expected to be $188.05M. It ranges from a high estimate of $197M to a low estimate of $175.1M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $164.88MFor the next quarter, 16 analysts are estimating revenue of $172.08M. There is a high estimate of $197.47M for the next quarter, whereas the lowest estimate is $145M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $667.91M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $655.17M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $795.59M in the next fiscal year. The high estimate is $886.7M and the low estimate is $675.4M.
